English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Medicine BioTech
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
Sep 26, 2021 20:00 HKT
Olympus Strengthens Surgical Portfolio with the Launch of POWERSEAL Advanced Bipolar Surgical Energy Devices
Sep 21, 2021 12:00 HKT
Olympus Strengthens Surgical Portfolio with the Launch of POWERSEAL Advanced Bipolar Surgical Energy Devices
Sep 21, 2021 12:00 HKT
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Sep 17, 2021 08:40 HKT
Hua and Sinopharm Announced Supply Chain Strategic Cooperation
Sep 15, 2021 14:35 HKT
Legend Capital Led a New Round of Investment of Etana
Sep 14, 2021 08:42 HKT
Legend Capital enjoys 4 MedTech IPOs in 1H2021, focusing on long-term and innovation investment
Sep 10, 2021 18:36 HKT
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
Sep 08, 2021 11:31 HKT
Cryoviva Singapore Expands Cord Blood Banking Services to Bahrain
Sep 07, 2021 12:20 HKT
New treatment option for schizophrenia Reagila(R) listed on PBS
Sep 06, 2021 06:00 HKT
Zhong Ji Longevity Science Announces 2021 Interim Results
Aug 31, 2021 09:36 HKT
Kintor Pharma Announces 2021 Interim Results
Aug 30, 2021 10:46 HKT
New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2%
Aug 21, 2021 14:02 HKT
Hua Medicine Announces 2021 Interim Results
Aug 19, 2021 17:31 HKT
TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million
Aug 13, 2021 09:00 HKT
Sihuan Pharmaceutical (0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' in China's Medical Aesthetics Industry
Aug 11, 2021 16:55 HKT
Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership
Aug 10, 2021 14:00 HKT
AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China
Aug 10, 2021 10:29 HKT
Hydrogel holds life-giving cells longer
Aug 06, 2021 23:00 HKT
Legend Capital invests in Series A funding round of BioMap, a biological computing platform
Jul 30, 2021 16:58 HKT
<< Previous  Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: